Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment
The DOI matches its Crossref record; 68 of the 90 references it cites were found in a registry or an index.
Abstract
Background: The design of anti-cancer therapies with high anti-tumour efficacy and reduced toxicity continues to be challenging. Anti-cancer prodrug and antibody-drug-conjugate (ADC) strategies that can specifically and efficiently deliver cytotoxic compounds to cancer cells have been used to overcome some of the challenges. The key to the success of many of these strategies is a self-immolative linker, which after activation can release the drug payload. Various types of triggerable self-immolative linkers are used in prodrugs and ADCs to improve their efficacy and safety. Objective: Numerous patents have reported the significance of self-immolative linkers in prodrugs and ADCs in cancer treatment. Based on the recent patent literature, we summarise methods for designing the site-specific activation of non-toxic prodrugs and ADCs in order to improve selectivity for killing cancer cells. Methods: In this review, an integrated view of the potential use of prodrugs and ADCs in cancer treatment are provided. This review presents recent patents and related publications over the past ten years uptill 2020. Results: The recent patent literature has been summarised for a wide variety of self-immolative PABC linkers, which are cleaved by factors including responding to the difference between the extracellular and intracellular environments (pH, ROS, glutathione) through over-expressed enzymes (cathepsin, plasmin, β-glucuronidase) or bioorthogonal activation. The mechanism for self-immolation involves the linker undergoing a 1,4- or 1,6-elimination (via electron cascade) or intramolecular cyclisation to release cytotoxic drug at the targeted site. Conclusion: This review provides the commonly used strategies from recent patent literature in the development of prodrugs based on targeted cancer therapy and antibody-drug conjugates, which show promise in therapeutic applications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“They put forward eight hallmarks of cancer along with two emerging characteristics namely; sustaining proliferative signalling, evading growth suppressors, avoiding immune destruction, enabling replicative immortality, activating invasion and metastasis, inducing angiogenesis, resisting cell death, deregulating cellul…”
BackgroundSiegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Photodynamic therapy of cancer: An update
Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., Hahn, S. M., Hamblin, M. R., Juzeniene, A., Kessel, D., et al. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20114 · Cited by 5,145
Cancer is a preventable disease that requires major lifestyle changes
Anand, P., Kunnumakara, A. B., Sundaram, C., Harikumar, K. B., Tharakan, S. T., Lai, O. S., Sung, B., & Aggarwal, B. B. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9661-9 · Cited by 2,632 · cited 1×
“The factors involved may be due to a genetic disorders, lifestylerelated factors such as tobacco smoke, diet, alcohol, UV radiation, environmental pollutants, infections, stress, obesity or physical inactivity [4].”
BackgroundA History of Cancer Chemotherapy
DeVita, V. T., & Chu, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6611 · Cited by 1,970 · cited 1×
“A new and significant turn to the treatment of tumours took place in the 20 century in the form of chemotherapy, with the use of nitrogen mustards and folic acid based drugs [10].”
BackgroundProdrugs: design and clinical applications
Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., & Savolainen, J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2468 · Cited by 1,630 · cited 1×
“Prodrugs have been reviewed in detail by others [12, 13], including a brief description of the types of prodrugs and their use in anti-cancer therapy.”
BackgroundThe expanding role of prodrugs in contemporary drug design and development
Rautio, J., Meanwell, N. A., Di, L., & Hageman, M. J. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.46 · Cited by 767 · cited 2×
“During the period 2008-2017, approximately 30 prodrugs were approved by the US Food and Drug Administration (FDA), which accounts for more than 12% of all small molecule new chemical entities [13].”
BackgroundCleavable linkers in antibody–drug conjugates
Bargh, J. D., Isidro-Llobet, A., Parker, J. S., & Spring, D. R. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00676h · Cited by 652 · cited 1×
“At the time of collating this review, there have been nine ADCs approved by the FDA namely trastuzumab deruxtecan (Enhertu®) [16], gemtuzumab ozogamicin (Mylotarg®), brentuximab vedotin (Adcetris®), trastuzumab emtansine (Kadcyla®), inotuzumab ozogamicin (Besponsa®) [17], polatuzumab vedotin-piiq (Polivy®) [18], enfor…”
MethodAntibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Staudacher, A. H., & Brown, M. P. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.367 · Cited by 540
Cited by
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
“Upon cleavage by lysosomal enzymes after ADC internalization into the target cells, the PABC spacer in the vc-PAB-MMAE linker/payload goes through a cascade of disassembly reactions and facilitates the release of untethered MMAE intracellularly [197].”
The Role of Oxidative Stress in Tumorigenesis and Progression
Li, K., Deng, Z., Lei, C., Ding, X., Li, J., & Wang, C. (2024) · Cells · doi:10.3390/cells13050441 · Cited by 152
Glycosidase activated prodrugs for targeted cancer therapy
Martin, H., Lázaro, L. R., Gunnlaugsson, T., & Scanlan, E. M. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00379a · Cited by 136
Linker Design for the Antibody Drug Conjugates: A Comprehensive Review
Lei, Y., Zheng, M., Chen, P., Chen, P., Loh, T., & Liu, H. (2025) · ChemMedChem · doi:10.1002/cmdc.202500262 · Cited by 88
Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies
He, J., Zeng, X., Wang, C., Wang, E., & Li, Y. (2024) · MedComm · doi:10.1002/mco2.671 · Cited by 76
“53,54 Additionally, the hydrophilicity or lipophilicity of the linker can influence payload coupling and reduce immunogenicity.”
Background
Metadata
- Authors
- Edupuganti, V. V. S. R., Tyndall, J. D. A., & Gamble, A. B.
- Affiliations
- School of Pharmacy, University of Otago, Dunedin 9054,New Zealand
- University of Otago (NZ)
- Corresponding author
- Tyndall, Joel D.A.
- Gamble, Allan B.
- Venue
- Recent Patents on Anti-Cancer Drug Discovery
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2021-11
- Volume
- 16
- Issue
- 4
- Pages
- 479-497
- ISSN
- 1574-8928 (ISSN-L)
- OpenAlex
- W3161294989
- Cited by
- 36
- References
- 90
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 4 · 2023: 6 · 2022: 2
- FWCI
- 0.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Recent Patents on Anti-Cancer Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Otago University Research Archive (University of Otago) (acceptedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and pharmacology of benzodiazepine derivatives
- Keywords
- self-immolative linker, prodrugs, antibody-drug conjugates, cancer therapy, reactive oxygen species, glutathione, plasmin, beta-glucuronidase, 1,4-elimination, 1,6-elimination, intramolecular cyclization, targeted cancer therapy
- MeSH terms
- Antineoplastic Agents, Humans, Neoplasms, Patents as Topic, Prodrugs, Drug Design, Drug Delivery Systems, Immunoconjugates, Cell Line, Tumor, Drug Liberation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment. https://app.cochat.ai/papers/10.2174/1574892816666210509001139
- The paper
- Edupuganti, V. V. S. R., Tyndall, J. D. A., & Gamble, A. B. (2021). Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment. Recent Patents on Anti-Cancer Drug Discovery. https://doi.org/10.2174/1574892816666210509001139
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.